Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price

Orchard Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 2016
Net Income
-150.66-144.58-151.98-163.42-230.5
Upgrade
Depreciation & Amortization
2.742.3321.681.2
Upgrade
Share-Based Compensation
16.0122.5427.9619.426.77
Upgrade
Other Operating Activities
55.92-5.38-4.26-23.81124.99
Upgrade
Operating Cash Flow
-75.99-125.1-126.27-166.13-97.54
Upgrade
Capital Expenditures
1.45-2.13-10.79-4.37-4.03
Upgrade
Change in Investments
89.11-29.15168.17-304.990
Upgrade
Other Investing Activities
--0.89---
Upgrade
Investing Cash Flow
90.56-32.17157.38-309.36-4.03
Upgrade
Share Issuance / Repurchase
0.21157.443.94133.59209.7
Upgrade
Debt Issued / Paid
-0.797.38024.470
Upgrade
Other Financing Activities
-0.12-6.75--0.61145.17
Upgrade
Financing Cash Flow
-0.69158.073.94157.45354.86
Upgrade
Exchange Rate Effect
-1.42-0.031.041.67-3.47
Upgrade
Net Cash Flow
12.460.7836.08-316.36249.83
Upgrade
Free Cash Flow
-74.54-127.23-137.07-170.5-101.57
Upgrade
Free Cash Flow Margin
-329.00%-7595.76%-5281.93%-6784.64%-4892.49%
Upgrade
Free Cash Flow Per Share
-5.82-10.26-13.78-18.29-45.02
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).